The purpose of this study is to assess the onset of action and effectiveness of DYMISTA® nasal spray in relieving your nasal and ocular allergy symptoms caused by ragweed pollen in an Environmental Exposure Unit/Chamber (EEC).
At least a 2-year medical history of allergy to ragweed
Not have current diagnosis of asthma
Not have received ragweed immunotherapy within the last 6 months
Other inclusion/exclusion criteria will be assessed
This study has been approved by Advarra Ethics Board
56 days total, 5 sessions
After the initial phone screening, in-clinic general screening will be conducted to confirm allergy to ragweed (compensation of $50 upon completion of visit procedures) and other procedures. Participants who screen pass general screening will be eligible to continue to the medical screening visit.
Up to $2325
4500 Dixie Rd Mississauga, Ontario, Canada, L4W 1N2